摘要:
Neuropeptide analogs and compositions including neuropeptide analogs are described herein. Also provided are methods of producing and using the neuropeptide analogs and compositions including one or more neuropeptide analogs.
摘要:
The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.
摘要:
Neuropeptide analogs and compositions including neuropeptide analogs are described herein. Also provided are methods of producing and using the neuropeptide analogs and compositions including one or more neuropeptide analogs.
摘要:
The invention relates to compounds which are used for diagnosing tumors comprised of conjugates of dyes having short-chain peptides that are derived from the vasoactive intestinal peptide, from somatostatin or from neurotensin. The invention also relates to the use of these compounds as optical diagnostic agents and to diagnostic products containing these compounds.
摘要:
Die Erfindung betrifft Verbindungen zur Tumordiagnostik, bestehend aus Konjugaten von Farbstoffen mit kurzkettigen Peptiden, die vom vasoaktiven intestinalen Peptid, vom Somatostatin oder vom Neurotensin abgeleitet sind, die Verwendung dieser Verbindungen als optische Diagnostika, und diese Verbindungen enthaltende diagnostische Mittel.
摘要翻译:血管活性肠肽(VIP),生长抑素或神经降压肽和聚甲基染料的缀合物(I)是新的。 式(I)的肽 - 染料缀合物是新的。 X =对应于VIP,生长抑素或神经降压素或其片段,衍生物或类似物的氨基酸序列的5-30α-,β-或γ-氨基酸(D或L)的序列,任选地被二硫键桥连 在两个半胱氨酸之间或通过N和C末端之间的酰胺桥; A 1 = H,乙酰基,1-10C烷基(任选被1-3个COOH基团和/或1-6个OH基团取代),包含2-30个CH 2 CH 2 O单元的聚氧乙烯基团或具有至少一个 吸收最大值在380-1200 nm范围内; 和A 2 = OH,NH 2或在380-1200nm范围内具有至少一个吸收最大值的聚甲基染料; 条件是A 1和A 2中的至少一个是聚甲炔染料,当A 1是聚甲炔染料时,其键合到N-末端氨基,并且当A 2是 聚甲炔染料,其在X内的任何位置键合到赖氨酸氨基或丝氨酸羟基。独立权利要求还包括以下内容:(1)诊断方法,包括向患者施用(I)静脉内或静脉内 通过喷雾或胃肠道,食管或膀胱喷雾,然后洗出多余的(I),然后通过在350-1200nm的激发波长处局部激发荧光进行内窥镜研究,并进行位点特异性检测 由染料发出的荧光; 和(2)式(II)的花青染料。 p = 1-3; n = 1-4或10; R 1,R 2 = 4-磺丁基,3-磺丙基,2-磺乙基,3-甲基-3-磺丙基,甲基,乙基或丙基; R 3 = H,COOE 1,CONE 1 E 2,NHCOE 1,NHCONHE 1,NE 1 E 2,OE 1,OSO 3 E 1, SO3E1或SO2NHE1; 和E 1,E 2 = H,CH 3,乙基或3-6 C烷基,其任选地被1-2个O原子和/或CO基团和/或任选地被1-5个OH基团取代。
摘要:
An aqueous physiologically active proteinaceous composition for lyophilization comprising: from about 150 to about 150,000 unit/ml of a covalently bound low diol polyalkylene oxide/protein, preferably polyethylene glycol/protein; from about 0.1 to about 20% w/v of cyclodextrin, preferably β-cyclodextrin; and from about 0.01 to about 50 mM buffer, said composition having a pH of from about 5.7 to about 6.5, is disclosed, together with a process for its preparation and its use for the preparation of a medicament for treating a disease condition caused by superoxide anions on tissue in a mammal.
摘要:
The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected from the following group consisting of; GVRAKAGVRNMFKSESY as set forth in SEQ ID NO: 9; GVRAKAGVRN(Nle)FKSESY as set forth in SEQ ID NO: 10; and YKSLRRKAPRWDAPLRDPALRQLL as set forth in SEQ ID NO: 11; and wherein at least one protecting group and/or at least one labelling agent is connected to said peptide compound.
摘要:
The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic selected from the group consisting of neurotensin, a neurotensin analog, or a neurotensin receptor agonist. The compounds of the invention can be used to treat any disease in which increased neurotensin activity is useful and can be used to induce hypothermia or analgesia.
摘要:
The present invention describes a system of gene carrier nanoparticles capable of specifically internalize into cancer cells, eg, cancer cells involved in breast cancer, in vitro and in vivo. The system described allows the introduction of therapeutic genes specifically into target cells through NSTR1 receptor-mediated endocytosis of said system, making it possible to provide treatment for this type of conditions, for example by systemic, intravenous, or in situ administration.